Clinical Trials

HIV/AIDSA Phase 3, Single-Arm Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Once-Yearly Intramuscular Lenacapavir for HIV Pre-exposure Prophylaxis (PrEP) in People with an Indication for PrEP (PURPOSE 365 GS-US-712-7286)
Not accepting volunteers
A Phase 3b, open label, randomized, standard-of-care control arm, multicenter, superiority study evaluating the efficacy, safety and tolerability of injectable CAB LA + RPV LA in viremic participants living with HIV-1 (ViiV Healthcare/GSK-CROWN-221611)
Not accepting volunteers
HIV/AIDSA Phase 3, Randomized, Open-Label, Active-Controlled Study to Evaluate a Switch to an Oral Weekly Islatravir/Lenacapavir Regimen in People With HIV-1 Who Are Virologically Suppressed on Standard of Care (GS-US-563-5926, ISLEND-2)
Not accepting volunteers
HIV/AIDSA Phase 3, Randomized, Double-blind, Active-controlled Study to Evaluate a Switch to an Oral Weekly Islatravir/Lenacapavir Regimen in People With HIV-1 Who Are Virologically Suppressed on Bictegravir/Emtricitabine/Tenofovir (B/F/TAF) (GS-US-563-5925, ISLEND-1)
Not accepting volunteers
HIV/AIDSPhase 3 Double-blind Multicenter Randomized Active-Controlled Study to Evaluate the Safety and Efficacy of Bictegravir/Lenacapavir Versus Biktarvy® (Bictegravir/Emtricitabine/Tenofovir Alafenamide) in Virologically Suppressed People With HIV-1 - GS-US-621-6290
Not accepting volunteers

Questions?

If you have any questions, please reach out to antiviralandvaccine@yale.eduor read our Frequently Asked Questions.